Jim Cramer: Pfizer Will Have a Long Road Ahead With Anacor Buy

Jim Cramer says he wouldn't be surprised if Allergan looked at buying Anacor before Pfizer decided to acquire the company for $5.2 billion, including debt.
Author:
Publish date:

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said he would not be surprised if Allergan (AGN) - Get Report looked at buying Anacor (ANAC) before Pfizer (PFE) - Get Report decided to acquire the company for $5.2 billion, including debt. Cramer said, 'the area of atopic dermatitis is a crowded field. I think people have to recognize that Pfizer may have decided that we have to buy someone. This is a very unusual acquisition because Pfizer has been building up its cancer franchise.'

At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.